Introduction and Objectives:
The intra-detrusor injection of Botulinum toxin-A (BTX-A) is becoming an accepted treatment option for the management of refractory detrusor overactivity (DO).
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2008 UroToday ® All Rights Reserved |





